Understanding that cancer is caused by mutations in genes that regulate cell proliferation has led to the development of targeted drug therapies.
A 3D model of BCR-ABL, an unregulated kinase that causes cancer.
A 3D model of gleevec-resistant BCR-ABL, a mutated form of BCR-ABL.
A 3D model of adenosine triphosphate, or ATP.
A 3D model of imatinib (Gleevec), a drug that mimics ATP and inhibits BCR-ABL.
A 3D model of dasatinib, a drug that can inhibit BCR-ABL and Gleevec-resistant BCR-ABL.
The drug Gleevec binds to and inactivates BCR-ABL, a mutant kinase that causes chronic myeloid leukemia.
Mutations in the BCR-ABL gene can cause resistance to Gleevec, but another drug, dasatinib, can be used instead.